Yearly Archives: 2024
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers
Ordaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design System
Carterra technology will allow Ordaōs to accelerate its mission of leveraging advanced technologies to efficiently and effectively design novel life-changing therapies for patients in need.
E&I Summit Recap
It was another banner year for the Wilson Sonsini Entrepreneur & Investor Life Sciences Summit (E&I Summit), presented by BioUtah and the University of Utah Technology Licensing Office. The 2024 E&I Summit included activities from March 13-15 with the main Summit event held, March 14 at the Sheraton in Salt Lake City. Over 450 registrants […]
MAUNA KEA TECHNOLOGIES PARTNERS WITH METRODORA TO CREATE FIRST U.S. CENTER OF EXCELLENCE FOR THE USE OF CELLVIZIO® TO IDENTIFY AND TREAT FOOD INTOLERANCE IN ADULTS
Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will serve as Center of Excellence for patient care and physician training to enable broad access to this breakthrough procedure Paris, Boston and Salt Lake City, March 6, 2024 – 5:45 […]
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Duchenne Muscular Dystrophy-Associated Cardiomyopathy
BOSTON, March 4, 2024 /PRNewswire/ — Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company’s phase 2 clinical trial of TXA127, the Company’s lead peptide product under development as a potential treatment for […]
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink
Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on April 30, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously […]
Renalytix Expands US Government Coverage for FDA Approved kidneyintelX.dkd Testing at $950
Data to be Presented Today at NGS Open Meeting Demonstrating Clinical Value of KidneyIntelX LONDON and SALT LAKE CITY, February 29, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) announces that effective March 1, 2024, the United States Government has approved adding the company’s Food and Drug Administration (“FDA”) de Novo Marketing authorized test, kidneyintelX.dkd, to its […]
Utah Legislative Recap, February 29, 2024
Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry. BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in […]
Owlet Announces $9 Million Private Placement Financing
LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT) (“Owlet” or the “Company”) announced today, following recent FDA clearances and strong preliminary fourth quarter results, that it has entered into definitive documentation relating to a sale of shares of its newly issued Series B convertible preferred stock (“Series B preferred stock”) and warrants to purchase its Class […]
PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) — PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II,” or “COVER DFUS II.” COVER DFUS […]
Utah Legislative Recap: February 23, 2024
Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry. BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create and […]
